Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Gustavo Werutsky

Citation

Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240

Authors

G. Werutsky1, M. Untch2, C. Hanusch3, P.A. Fasching4, J. Blohmer5, S. Seiler6, C. Denkert7, H. Tesch8, C. Jackisch9, B. Gerber10, A. Schneeweiss11, T. Link12, J. Huober13, K. Rhiem14, V. Vladimirova6, V. Nekljudova6, S. Loibl6

Author affiliations

  • 1 Medical Oncology, Latin American Cooperative Oncology Group (LACOG), 90619-900 - Porto Alegre/BR
  • 2 Clinic For Gynecology, Gynecologic Oncology And Obstetrics, Helios Klinikum Berlin Buch, 13125 - Berlin/DE
  • 3 Gynäkologie Und Geburtshilfe, Klinikum zum Roten Kreuz München, Germany, 80634 - München/DE
  • 4 Gynecology And Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen/DE
  • 5 Gynäkologie Mit Brustzentrum, Charité-Universitätsmedizin, Berlin, 10113 - Berlin/DE
  • 6 Department Of Medicine And Research, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
  • 7 Institut Für Pathologie Ukgm, , Universitätsklinikum Marburg, 35037 - Marburg/DE
  • 8 Centrum Für Hämatologie Und Onkologie, Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, 60389 - Frankfurt am Main/DE
  • 9 Gynäkologie Und Geburtshilfe, Klinikum Offenbach GmbH, 63069 - Offenbach am Main/DE
  • 10 Gynäkologie Und Geburtshilfe, Universitätsfrauenklinik am Klinikum Südstadt, 18059 - Rostock/DE
  • 11 Gynecologic Oncology, Nationales Centrum für Tumorerkrankungen Heidelberg, 69115 - Heidelberg/DE
  • 12 Frauenheilkunde U.geburtshilfe, Universitätsklinikum Dresden, 01307 - Dresden/DE
  • 13 Dept Of Gynecology, Breast Center, Universitaetsfrauenklinik Ulm, 89075 - Ulm/DE
  • 14 Zentrum Familiärer Brust- Und Eierstockkrebs, Uniklinik Köln, 50931 - Köln/DE
More

Resources

Abstract 3792

Background

LRR after neoadjuvant chemotherapy (NACT) for BC may impact patient’s outcome. This study aimed to evaluate the rates of LRR as first event after NACT and to identify independent predictors of LRR.

Methods

A total of 10075 women with primary BC and available follow-up from 9 prospective neoadjuvant trials were included in the pooled analysis. The main endpoint was cumulative incidence rates of LRR as first event after NACT; distant recurrence, secondary malignancy or death was defined as competing event. To identify predictors of LRR, surgery type, pathological complete response (pCR=ypT0 ypN0), BC subtypes and other risk factors were evaluated using Fine-Gray’s regression model. The two-sided significance level was set to α = 0.05.

Results

After a median follow-up in the entire cohort of 67 months (range 0-215 months), 959 (9.5%) LRRs as first event were observed. Age ( < =50 vs > 50 years; p < 0.001), clinical nodal status (cN- vs cN+; p < 0.001), tumour grade (G1-2 vs G3; p = 0.001), pCR (no vs yes; p < 0.001) and BC subtypes (HR+/HER2- vs HR+/HER2+, HR-/HER2+, TNBC; p < 0.001) but not surgery type (BCS vs mastectomy; p = 0.514) were significant independent predictors of LRR in multivariate analysis. LRR rates among BC subtypes were lower in pts achieving pCR vs non-pCR: HR+/HER2- (3.9% vs 5.9%; HR = 0.56 [95%CI 0.32-0.98]; p = 0.043); HR+/HER2 + (4.8% vs 8.1%; HR = 0.61 [95%CI 0.37-1.02]; p = 0.058); HR-/HER2 + (3.1% vs 14.8%; HR = 0.22 [94%CI 0.12-0.39]; p < 0.001) and in TNBC (4.2% vs 18.5%; HR = 0.25 [95%CI 0.18-0.35]; p < 0.001). Within the non-pCR subgroup, LRR rates were significantly higher in pts with HR-/HER2+ and TNBC vs HR+/HER2- BC (HR = 2.34 [95%CI 1.83-2.99]; p < 0.001 and HR = 3.02 [95%CI 2.54-3.60]; p < 0.001, respectively) as well as in pts treated with mastectomy than with BCS (HR = 1.22 [95%CI 1.06-1.1.41]; p = 0.007).

Conclusions

Young age, node-positive and G3 tumours as well as non-pCR status and TNBC were found to significantly increase the risk of LRR as first event after NACT. Pts with HR-/HER2+ and TNBC not achieving pCR were at highest risk of LRR. Hence, these BC subtypes might be considered for additional post-neoadjuvant treatment approaches.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

German Breast Group (GBG).

Funding

Has not received any funding.

Disclosure

M. Untch: Honoraria (institution), non-financial support: Abbvie; Honoraria (institution), non-financial support: Amgen GmbH; Honoraria (institution), non-financial support: AstraZeneca; Honoraria (institution): BMS; Honoraria (institution), non-financial support: Celgene GmbH; Honoraria (institution), non-financial support: Daiji Sankyo; Honoraria (institution), non-financial support: Eisai GmbH; Honoraria (institution), non-financial support: Janssen Cilag; Honoraria (institution), non-financial support: TEVA Pharmaceuticals Ind Ltd; Honoraria (institution): Lilly Deutschland; Honoraria (institution), non-financial support: Sividon Diagnostics; Honoraria (institution), non-financial support: MSD Merck; Honoraria (institution), non-financial support: Mundipharma; Honoraria (institution), non-financial support: Myriad Genetics; Honoraria (institution), non-financial support: Odonate; Honoraria (institution), non-financial support: Pfizer GmbH; Honoraria (institution): PUMA Biotechnology; Honoraria (institution), non-financial support: Novartis; Honoraria (institution), non-financial support: Roche Pharma AG; Honoraria (institution), non-financial support: Sanofi Aventis Deutschland GmbH. C. Hanusch: Honoraria (self), Outside the submitted work: Roche; Honoraria (self), Outside the submitted work: Pfizer; Honoraria (self), Outside the submitted work: Novartis; Honoraria (self), Outside the submitted work: Celgene; Honoraria (self), Outside the submitted work: Lilly; Honoraria (self), Outside the submitted work: AstraZeneca. P.A. Fasching: Research grant / Funding (institution), The Work Under Consideration for Publication: Novartis; Research grant / Funding (institution), The Work Under Consideration for Publication: Biontech; Honoraria (self), The Work Under Consideration for Publication: Novartis; Honoraria (self), The Work Under Consideration for Publication: Roche; Honoraria (self), The Work Under Consideration for Publication: Pfizer; Honoraria (self), The Work Under Consideration for Publication: Celgene; Honoraria (self), The Work Under Consideration for Publication: Daiichi-Sankyo; Honoraria (self), The Work Under Consideration for Publication: TEVA; Honoraria (self), The Work Under Consideration for Publication: AstraZeneca; Honoraria (self), The Work Under Consideration for Publication: Merck Sharp & Dohme; Honoraria (self), The Work Under Consideration for Publication: Myelo Therapeutics; Honoraria (self), The Work Under Consideration for Publication: Macrogenics; Honoraria (self), The Work Under Consideration for Publication: Eisai; Honoraria (self), The Work Under Consideration for Publication: Puma; Research grant / Funding (institution), The Work Under Consideration for Publication: Cepheid. S. Seiler: Honoraria (self), presentations: Roche; Advisory / Consultancy: Amgen GmbH; Advisory / Consultancy: Hexal; Honoraria (self): Mundipharma; Non-remunerated activity/ies: Novartis. C. Denkert: Shareholder / Stockholder / Stock options: Sividon Diagnostics; Honoraria (self): Teva; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self), Advisory / Consultancy: Amgen; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: Daiichi Sankyo; Licensing / Royalties: VMScope digital pathology software; Licensing / Royalties: Patent application: EP18209672 - cancer immunotherapy; Licensing / Royalties: Patent application EP20150702464 - therapy response; Licensing / Royalties: Patent application EP20150702464 - therapy response. H. Tesch: Honoraria (self): Vifor; Honoraria (self): Roche; Honoraria (self): Amgen. C. Jackisch: Honoraria (self), Travel / Accommodation / Expenses: Celgene; Honoraria (self): Roche. A. Schneeweiss: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Molecular Partner; Honoraria (self), Speaker Bureau / Expert testimony: AstraZeneca; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self): Novartis; Honoraria (self): MSD; Honoraria (self): Tesaro; Honoraria (self): Lilly. T. Link: Honoraria (self): Amgen; Non-remunerated activity/ies: AstraZeneca; Honoraria (self), Non-remunerated activity/ies: Pfizer; Non-remunerated activity/ies: Pharma Mar; Non-remunerated activity/ies: Daiichi Sankyo; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): Teva; Honoraria (self): Tesaro; Honoraria (self), Non-remunerated activity/ies: Roche. J. Huober: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy: Hexal; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: MSD Oncology; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy: Abbvie. K. Rhiem: Honoraria (self): Tesaro; Honoraria (self): Pfizer; Honoraria (self): AstraZeneca. S. Loibl: Honoraria (institution), Research grant / Funding (institution), The Work Under Consideration for Publication: Roche; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: AbbVie; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: Amgen; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: AstraZeneca; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: Celgene; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: Novartis; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: Pfizer; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: Seattle Genetics; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: Teva; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: Vifor; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: PRIME; Honoraria (institution), Research grant / Funding (institution), Relevant financial activities outside the submitted work: Daiichi; Licensing / Royalties, Intellectual Property - Patents & Copyrights: EP14153692.0 pending. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings